On August 19, 2019, nearly 200 chief executives met to redefine the purpose and role of businesses in society. The outcome of this meeting was a paradigm shift from the long-held corporate orthodoxy that shareholders’ interests are supreme to a standard that promotes “an economy that serves all Americans.” Although not entirely a new phenomenon, the Business Roundtable emphasized impact investing as a way to tackle the world’s most pressing problems – from climate change, violence, and poverty to social injustice. Impact investments, as defined by the Global Impact Investing Network (GIIN), are “investments made with the intention to generate positive, measurable social and environmental impact alongside a financial return.” The goal of impact investing is to use the market to correct and address some of society’s most intractable problems. Impact investing combines traditional investment vehicles with philanthropy motivation, breaking with decades of long-held beliefs of shareholder primacy.
By Kati Pajak
“Men” is not synonymous to “person”, nor does “he” mean “she.” It is important for contractual language to be not only precise but also accurate. Many agreements govern multiple individuals, some of whose gender is unclear or variable. This article will give you advice and guidance on how to adjust contract language to be gender neutral (and how Mintz can help through the process). As society moves towards treating all genders equally, legal contracts should too.
Artificial Intelligence (AI) inventions have aided development in nearly every industry, but perhaps none more so than synthetic biology. For synthetic biology researchers, AI has developed into a vital tool to create cutting edge applications. Growth is expected to accelerate with the AI healthcare market set to reach $6.6 billion by 2021, a 40 percent growth from its current size. Biotech and synthetic biology companies that use AI and investors in these companies should be aware of various legal aspects related to patenting. This blog is part 1 of a multi-part series that explores various patenting considerations for AI in biotech and synthetic biology.
Artificial Intelligence (AI) is increasingly becoming important across a diverse spectrum of technologies and businesses. As AI grows in importance in business and technology, so too grows the number of patent applications and the potential for uncertainty. Therefore, the U.S. Patent and Trademark Office (USPTO) must continue to ensure the appropriate balance in the administration of our IP system. To help achieve that appropriate balance, the USPTO recently published a notice to the Federal Register (“Notice”) posing questions regarding the intersection of patent law with AI.
Private companies often adopt equity incentive plans in order to issue stock options to their employees, directors and consultants. However, once the plan is adopted, there are a number of things that a Company should consider when granting stock options. This article provides a list of questions for private companies to consider when issuing stock options under an equity incentive plan.